2 Growth Stocks for In-the-Know Investors
The genetic testing industry has been synonymous with growth in recent years. Advances in high-volume DNA sequencing, data interpretation, health insurance coverage, and pharmaceutical company partnerships have combined to create profitable businesses with ample long-term growth opportunities.
Not all genetic testing companies are created equal, however. NeoGenomics (NASDAQ: NEO) is the only dedicated oncology reference lab with a comprehensive testing menu, offering physicians and companies running clinical trials access to a powerful platform for peering into the human genome. Meanwhile, Invitae (NYSE: NVTA) is building a platform capable of screening individuals for a broad array of diseases, then helping them to interpret the data. It's even making a relatively unconventional bet that clinical-grade, direct-to-consumer genetic testing will take off in the near future.
Here's why investors should keep an eye on these two growth stocks.
Source Fool.com
